Keywords : thyroid cancer, cancer
This report provides data on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer . 'Thyroid Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, invest...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
This report provides data on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer . 'Thyroid Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope of the Research
- A snapshot of the global therapeutic scenario for Thyroid Cancer .
- A review of the Thyroid Cancer products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Thyroid Cancer .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Thyroid Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Global Pathology Industry
Table of Contents
Data table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global March kets Direct Report Coverage 7
Thyroid Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Thyroid Cancer 9
Thyroid Cancer Therapeutics under Development by Firms 11
Thyroid Cancer Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20
Thyroid Cancer Therapeutics – Products under Development by Firms 21
Thyroid Cancer Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Thyroid Cancer Therapeutics Development 24
F. Hoffmann-La Roche Ltd. 24
Amgen Inc. 25
Daiichi Sankyo Firms, Ltd 26
Bio-Path Holdings, Inc. 27
November artis AG 28
Eisai Co., Ltd. 29
Pfizer Inc. 30
Exelixis, Inc. 31
Bayer AG 32
OXiGENE, Inc. 33
Vascular Biogenics Ltd. 34
Globeimmune, Inc. 35
Thyroid Cancer – Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
E7080 - Drug Profile 42
Motesanib - Drug Profile 44
Nexavar - Drug Profile 46
Inlyta - Drug Profile 48
Caprelsa - Drug Profile 50
LBH589 - Drug Profile 52
Zelboraf - Drug Profile 55
Cabozantinib - Drug Profile 57
VB-111 - Drug Profile 59
BP-100-2.01 - Drug Profile 60
R935788 - Drug Profile 61
CP-4033 - Drug Profile 62
Gleevec + Dacarbazine + Xeloda - Drug Profile 63
ZD6474 - Drug Profile 65
Iressa - Drug Profile 67
GI-6207 - Drug Profile 68
BAY 43-9006 - Drug Profile 69
Gleevec - Drug Profile 70
Pazopanib Hydrochloride - Drug Profile 71
Romidepsin - Drug Profile 73
BAY43-9006 - Drug Profile 75
Gleevec - Drug Profile 76
Tanespimycin - Drug Profile 77
Lithium Carbonate - Drug Profile 79
XL184 + Rosiglitazone - Drug Profile 80
Temsirolimus + Sorafenib - Drug Profile 81
Depakote - Drug Profile 82
Irinotecan - Drug Profile 83
Thalidomide - Drug Profile 85
Afinitor - Drug Profile 86
Hydroxyurea + Fluorouracil + Paclitaxel + G-CSF + Radiation Therapy - Drug Profile 87
Recombinant thyrotropin - Drug Profile 88
Almita + Paclitaxel - Drug Profile 89
Zybrestat + Carboplatin + Paclitaxel - Drug Profile 90
LBH589 - Drug Profile 92
RAD001 - Drug Profile 93
Temsirolimus + Vinorelbine Ditartrate - Drug Profile 94
Valproic Acid - Drug Profile 95
Aplidin - Drug Profile 96
Aflibercept + Radiation theraphy - Drug Profile 97
Everolimus + Sorafenib - Drug Profile 99
Fostamatinib - Drug Profile 100
Sunitinib - Drug Profile 101
Prednisone + Thalidomide - Drug Profile 102
Sorafenib Tosylate - Drug Profile 104
SU011248 - Drug Profile 105
Sunitinib - Drug Profile 106
Lithium Carbonate - Drug Profile 107
AG-013736 - Drug Profile 108
Bortezomib - Drug Profile 109
Rosiglitazone Maleate - Drug Profile 110
Cisplatin + EPC2407 - Drug Profile 111
Sutent - Drug Profile 112
Cediranib + Lenalidomide - Drug Profile 113
CS-7017 + Paclitaxel - Drug Profile 114
Avastin + Doxorubicin - Drug Profile 116
Alimta + Paclitaxel - Drug Profile 117
ET-D5 - Drug Profile 118
Everolimus + SOM230 - Drug Profile 119
Pazopanib + Iodine I 131 - Drug Profile 120
Thalidomide - Drug Profile 121
Pazopanib + GSK1120212 - Drug Profile 122
Thyroid Cancer Therapeutics – Drug Profile Updates 123
Thyroid Cancer Therapeutics – Discontinued Products 139
Thyroid Cancer Therapeutics - Dormant Products 140
Thyroid Cancer – Product Development Milestones 141
Featured News & Press Releases 141
Appendix 150
Methodology 150
Coverage 150
Secondary Research 150
Primary Research 150
Expert Panel Validation 150
Contact Us 151
Disclaimer 151
List of Tables
Number of Products Under Development for Thyroid Cancer, H1 2012 13
Products under Development for Thyroid Cancer – Comparative Analysis, H1 2012 14
Number of Products under Development by Firms, H1 2012 16
Number of Products under Development by Firms, H1 2012 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H1 2012 19
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 20
Comparative Analysis by Late Stage Development, H1 2012 21
Comparative Analysis by Mid Clinical Stage Development, H1 2012 22
Comparative Analysis by Early Clinical Stage Development, H1 2012 23
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 24
Products under Development by Firms, H1 2012 25
Products under Investigation by Universities/Institutes, H1 2012 26
F. Hoffmann-La Roche Ltd., H1 2012 28
Amgen Inc., H1 2012 29
Daiichi Sankyo Firms, Ltd, H1 2012 30
Bio-Path Holdings, Inc., H1 2012 31
November artis AG, H1 2012 32
Eisai Co., Ltd., H1 2012 33
Pfizer Inc., H1 2012 34
Exelixis, Inc., H1 2012 35
Bayer AG, H1 2012 36
OXiGENE, Inc., H1 2012 37
Vascular Biogenics Ltd., H1 2012 38
Globeimmune, Inc., H1 2012 39
Assessment by Monotherapy Products, H1 2012 40
Assessment by Combination Products, H1 2012 41
Assessment by Stage and Route of Administration, H1 2012 43
Assessment by Stage and Molecule Type, H1 2012 45
Thyroid Cancer Therapeutics – Drug Profile Updates 127
Thyroid Cancer Therapeutics – Discontinued Products 143
Thyroid Cancer Therapeutics – Dormant Products 144
List of Figures
Number of Products under Development for Thyroid Cancer, H1 2012 13
Products under Development for Thyroid Cancer – Comparative Analysis, H1 2012 14
Products under Development by Firms, H1 2012 15
Products under Investigation by Universities/Institutes, H1 2012 18
Late Stage Products, H1 2012 21
Mid Clinical Stage Products, H1 2012 22
Early Clinical Stage Products, H1 2012 23
Pre-Clinical Stage Products, H1 2012 24
Assessment by Monotherapy Products, H1 2012 40
Assessment by Combination Products, H1 2012 41
Assessment by Route of Administration, H1 2012 42
Assessment by Stage and Route of Administration, H1 2012 43
Assessment by Molecule Type, H1 2012 44
Assessment by Stage and Molecule Type, H1 2012 45
